Health Canada Approves NEUPRO® (rotigotine) Patch For Treatment Of Parkinson's Disease And Restless Legs Syndrome
Novel dosage form represents new treatment for Parkinson's with efficacy in motor symptoms of the disease
OAKVILLE, ON, April 2, 2013 /CNW/ - UCB Canada Inc. announced today that Health Canada has approved NEUPRO® (rotigotine), the first and only non-ergolinic dopamine agonist available in a patch, to treat the signs and symptoms of idiopathic Parkinson's disease (PD) and moderate-to-severe idiopathic restless legs syndrome (RLS), also known as Willis-Ekbom disease, in adults.
NEUPRO® is the first new treatment for Parkinson's disease approved by Health Canada in five years and provides 24-hour delivery of rotigotine through the skin into the blood stream. NEUPRO® has demonstrated efficacy in managing motor symptoms associated with Parkinson's disease.
"The ability to ensure a steady 24-hour delivery of medication with NEUPRO® may help to reduce debilitating on and off symptoms which many patients experience with Parkinson's treatments," says Dr. David Grimes, Director, Parkinson's Disease and Movement Disorders Clinic at the Ottawa Hospital. "The impact of sustained symptom control in the morning and in the evening can have a substantial effect on a patient's quality of life."UCB Canada Inc. is undertaking all measures required to supply the Canadian market with NEUPRO. "Parkinson Society Canada is pleased to learn that Canadians living with Parkinson's now have another treatment option to help manage the symptoms of this chronic disease," says Joyce Gordon, President and CEO, Parkinson Society Canada. "With innovative therapies such as NEUPRO® and ongoing research into the causes of this disease, we will help to ensure a brighter future and better quality of life for Canadians living with Parkinson's." Although the precise mechanisms of action of NEUPRO® as treatment for PD and RLS are unknown, as a PD treatment, the mechanism of action is thought to be related to increasing the activities of the dopamine receptors within the caudate-putamen, the region of the brain that regulates movement. Similarly, in RLS, the mechanism of action of NEUPRO® is thought to be related to its ability to stimulate dopamine receptors.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts